WallStreetZenWallStreetZen

NASDAQ: UPB
Upstream Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their UPB stock forecasts and price targets.

Forecast return on equity

Is UPB forecast to generate an efficient return?

Company
-27.77%
Industry
140.91%
Market
90.47%
UPB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is UPB forecast to generate an efficient return on assets?

Company
-27.12%
Industry
32.45%
UPB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

UPB earnings per share forecast

What is UPB's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$2.57
Avg 2 year Forecast
-$2.92
Avg 3 year Forecast
-$2.65

UPB revenue forecast

What is UPB's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$1.8M
Avg 2 year Forecast
$3.0M
Avg 3 year Forecast
$3.2M

UPB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
UPB$11.36N/AN/A
TRVI$6.09$21.07+245.99%Strong Buy
EYPT$9.03$27.00+199.00%Strong Buy
STOK$11.53$27.00+134.17%Strong Buy
BCAX$10.84$23.25+114.51%Buy
View Top Biotech Stocks

Upstream Bio Stock Forecast FAQ

What is UPB's earnings growth forecast for 2025-2027?

(NASDAQ: UPB) Upstream Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Upstream Bio's earnings in 2025 is N/A.On average, 4 Wall Street analysts forecast UPB's earnings for 2025 to be -$138,115,332, with the lowest UPB earnings forecast at -$140,401,565, and the highest UPB earnings forecast at -$135,022,195. On average, 4 Wall Street analysts forecast UPB's earnings for 2026 to be -$157,077,613, with the lowest UPB earnings forecast at -$167,836,353, and the highest UPB earnings forecast at -$145,242,998.

In 2027, UPB is forecast to generate -$142,553,313 in earnings, with the lowest earnings forecast at -$152,774,117 and the highest earnings forecast at -$126,415,202.

If you're new to stock investing, here's how to buy Upstream Bio stock.

What is UPB's revenue growth forecast for 2025-2027?

(NASDAQ: UPB) Upstream Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Upstream Bio's revenue in 2025 is N/A.On average, 2 Wall Street analysts forecast UPB's revenue for 2025 to be $94,945,886, with the lowest UPB revenue forecast at $30,662,411, and the highest UPB revenue forecast at $159,229,361. On average, 1 Wall Street analysts forecast UPB's revenue for 2026 to be $162,456,983, with the lowest UPB revenue forecast at $162,456,983, and the highest UPB revenue forecast at $162,456,983.

In 2027, UPB is forecast to generate $169,450,164 in revenue, with the lowest revenue forecast at $169,450,164 and the highest revenue forecast at $169,450,164.

What is UPB's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: UPB) forecast ROA is -27.12%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is UPB's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: UPB) Upstream Bio's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that UPB's EPS will be -$2.57 for 2025, with the lowest EPS forecast at -$2.61, and the highest EPS forecast at -$2.51. On average, analysts forecast that UPB's EPS will be -$2.92 for 2026, with the lowest EPS forecast at -$3.12, and the highest EPS forecast at -$2.70. In 2027, UPB's EPS is forecast to hit -$2.65 (min: -$2.84, max: -$2.35).

What is UPB's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: UPB) forecast ROE is -27.77%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.